Human immunodeficiency virus (HIV)-specific effector CD8 T cell activity in patients with primary HIV infection

J Infect Dis. 2002 Mar 15;185(6):755-65. doi: 10.1086/339338. Epub 2002 Feb 20.

Abstract

The interferon-gamma ELISPOT assay was used to assess and compare the magnitude and breadth of human immunodeficiency virus (HIV)-specific CD8 T cell responses in treatment-naive subjects during the first year of HIV primary infection and during the chronic phase of infection. Twenty-five subjects tested within a year of exposure to HIV resulting in seroconversion and 20 subjects with chronic infection were screened for HIV peptide-specific activity by stimulating peripheral blood mononuclear cells with a panel of 5-21 HLA class I-restricted HIV peptides (mean, 11.2 +/- 3.5 HIV peptides). There was a significant correlation between the magnitude and breadth of HIV-specific effector responses and time elapsed from exposure (r=0.63 for magnitude vs. time and r=0.64 for breadth vs. time; P<.02, paired t test). Maximal breadth of the HIV gene product reactivity was achieved within 2 months of exposure for Nef-specific responses and by 4 months of exposure for responses directed to Env, Gag, and reverse transcriptase.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • AIDS Vaccines / immunology
  • Adult
  • Amino Acid Sequence
  • CD4 Lymphocyte Count
  • CD8-Positive T-Lymphocytes / immunology*
  • HIV / immunology*
  • HIV Infections / immunology*
  • HLA-A Antigens / analysis
  • Humans
  • Male
  • Middle Aged
  • Molecular Sequence Data

Substances

  • AIDS Vaccines
  • HLA-A Antigens